493 related articles for article (PubMed ID: 9865924)
1. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
2. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
Beall HD; Murphy AM; Siegel D; Hargreaves RH; Butler J; Ross D
Mol Pharmacol; 1995 Sep; 48(3):499-504. PubMed ID: 7565631
[TBL] [Abstract][Full Text] [Related]
3. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
4. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
5. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
6. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
7. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
8. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
Cummings J; Ritchie A; Butler J; Ward TH; Langdon S
Anticancer Res; 2003; 23(5A):3979-83. PubMed ID: 14666706
[TBL] [Abstract][Full Text] [Related]
9. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.
Ross D; Beall H; Traver RD; Siegel D; Phillips RM; Gibson NW
Oncol Res; 1994; 6(10-11):493-500. PubMed ID: 7620217
[TBL] [Abstract][Full Text] [Related]
10. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
11. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
12. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
13. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
14. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
[TBL] [Abstract][Full Text] [Related]
15. The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells.
Qiu XB; Cadenas E
Arch Biochem Biophys; 1997 Oct; 346(2):241-51. PubMed ID: 9343371
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.
Traver RD; Horikoshi T; Danenberg KD; Stadlbauer TH; Danenberg PV; Ross D; Gibson NW
Cancer Res; 1992 Feb; 52(4):797-802. PubMed ID: 1737339
[TBL] [Abstract][Full Text] [Related]
17. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
18. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
Fryatt T; Pettersson HI; Gardipee WT; Bray KC; Green SJ; Slawin AM; Beall HD; Moody CJ
Bioorg Med Chem; 2004 Apr; 12(7):1667-87. PubMed ID: 15028260
[TBL] [Abstract][Full Text] [Related]
19. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł.
Malkinson AM; Siegel D; Forrest GL; Gazdar AF; Oie HK; Chan DC; Bunn PA; Mabry M; Dykes DJ; Harrison SD
Cancer Res; 1992 Sep; 52(17):4752-7. PubMed ID: 1324793
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
